Host response mediators in coronavirus infection – ARBs CORONA II

A pan-Canadian randomzied controlled trial of an ARB (losartan) vs. usual care and mortality of COVID-19. Evaluation of ACE pathway proteins, proteomics and metabolomics as biomarkes of response to losartan and outome of COVID-19.

More details on the clinical trial can be found here.